Strong_Recording3210

Thank you very much for this detailed response, Mr. Kersten! You are a true cancer immunotherapy pioneer pushing ahead in a field so many others have doubted for far too long.

Do you believe the FDA will take the differences you cited into consideration when they look at potential approval for Multikine?

Can you share any more insight or perspective on how the data was received at ASCO by physicians?

Is the company still for sale at a reasonable price?

What type of partnership would you entertain and what would that investment look like?

MacroGenics recently acknowledged the deaths of seven patients in their Phase II trial assessing combinations of enoblituzumab with either retifanlimab or tebotelimab as first-line treatments of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Given the positive safety and efficacy of Multikine during P3, does this further establish CEL-SCI as the only true player in SCCHN?